Does perioperative chemotherapy improve survival in upper tract urothelial carcinoma? A population based analysis

OBJECTIVES: To evaluate the utilization and outcomes of perioperative chemotherapy in non-metastatic UTUC patients over the past decade using a large national database. METHODS: All patients aged 18 and older diagnosed with non-metastatic UTUC between 2004 and 2013 were identified within the Surveil...

Descripción completa

Detalles Bibliográficos
Autores principales: Goldberg, Hanan, Klaassen, Zachary, Chandrasekar, Thenappan, Sayyid, Rashid, Kulkarni, Girish S., Hamilton, Robert J., Fleshner, Neil E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5922356/
https://www.ncbi.nlm.nih.gov/pubmed/29721162
http://dx.doi.org/10.18632/oncotarget.24694
_version_ 1783318183583678464
author Goldberg, Hanan
Klaassen, Zachary
Chandrasekar, Thenappan
Sayyid, Rashid
Kulkarni, Girish S.
Hamilton, Robert J.
Fleshner, Neil E.
author_facet Goldberg, Hanan
Klaassen, Zachary
Chandrasekar, Thenappan
Sayyid, Rashid
Kulkarni, Girish S.
Hamilton, Robert J.
Fleshner, Neil E.
author_sort Goldberg, Hanan
collection PubMed
description OBJECTIVES: To evaluate the utilization and outcomes of perioperative chemotherapy in non-metastatic UTUC patients over the past decade using a large national database. METHODS: All patients aged 18 and older diagnosed with non-metastatic UTUC between 2004 and 2013 were identified within the Surveillance, Epidemiology and End Results (SEER) database. Relevant clinical data was collected and predictors of cancer specific mortality (CSM) and other cause mortality (OCM) were analyzed. RESULTS: The total cohort included 8,762 patients. Of these, 1,402 (16%) patients received chemotherapy, including only 35% of high-risk patients (>pT2 or N1). Treated patients had higher CSM (21.3% vs. 13.1%, p<0.001). Predictors of chemotherapy utilization included residence in Midwest states, tumor located in the ureter, higher stage and grade. Predictors of CSM included older age, residence in southern states, receipt of chemotherapy (HR = 1.151, 95% CI: 1.003-1.32, p=0.044), higher stage and grade. OCM was predicted by male gender, older age, ureteral tumor, and higher stage. A subset analysis of patients younger than 65 showed similar predictors, while an analysis of high risk patients demonstrated that chemotherapy receipt did not predict CSM or OCM. CONCLUSIONS: In this large contemporary non-metastatic UTUC cohort, chemotherapy utilization was found to be quite infrequent, but increasing steadily. Perioperative chemotherapy had no effect on CSM in high-risk patients, while correlated to higher CSM in the younger patients.
format Online
Article
Text
id pubmed-5922356
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Impact Journals LLC
record_format MEDLINE/PubMed
spelling pubmed-59223562018-05-02 Does perioperative chemotherapy improve survival in upper tract urothelial carcinoma? A population based analysis Goldberg, Hanan Klaassen, Zachary Chandrasekar, Thenappan Sayyid, Rashid Kulkarni, Girish S. Hamilton, Robert J. Fleshner, Neil E. Oncotarget Research Paper OBJECTIVES: To evaluate the utilization and outcomes of perioperative chemotherapy in non-metastatic UTUC patients over the past decade using a large national database. METHODS: All patients aged 18 and older diagnosed with non-metastatic UTUC between 2004 and 2013 were identified within the Surveillance, Epidemiology and End Results (SEER) database. Relevant clinical data was collected and predictors of cancer specific mortality (CSM) and other cause mortality (OCM) were analyzed. RESULTS: The total cohort included 8,762 patients. Of these, 1,402 (16%) patients received chemotherapy, including only 35% of high-risk patients (>pT2 or N1). Treated patients had higher CSM (21.3% vs. 13.1%, p<0.001). Predictors of chemotherapy utilization included residence in Midwest states, tumor located in the ureter, higher stage and grade. Predictors of CSM included older age, residence in southern states, receipt of chemotherapy (HR = 1.151, 95% CI: 1.003-1.32, p=0.044), higher stage and grade. OCM was predicted by male gender, older age, ureteral tumor, and higher stage. A subset analysis of patients younger than 65 showed similar predictors, while an analysis of high risk patients demonstrated that chemotherapy receipt did not predict CSM or OCM. CONCLUSIONS: In this large contemporary non-metastatic UTUC cohort, chemotherapy utilization was found to be quite infrequent, but increasing steadily. Perioperative chemotherapy had no effect on CSM in high-risk patients, while correlated to higher CSM in the younger patients. Impact Journals LLC 2018-04-10 /pmc/articles/PMC5922356/ /pubmed/29721162 http://dx.doi.org/10.18632/oncotarget.24694 Text en Copyright: © 2018 Goldberg et al. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/) 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Paper
Goldberg, Hanan
Klaassen, Zachary
Chandrasekar, Thenappan
Sayyid, Rashid
Kulkarni, Girish S.
Hamilton, Robert J.
Fleshner, Neil E.
Does perioperative chemotherapy improve survival in upper tract urothelial carcinoma? A population based analysis
title Does perioperative chemotherapy improve survival in upper tract urothelial carcinoma? A population based analysis
title_full Does perioperative chemotherapy improve survival in upper tract urothelial carcinoma? A population based analysis
title_fullStr Does perioperative chemotherapy improve survival in upper tract urothelial carcinoma? A population based analysis
title_full_unstemmed Does perioperative chemotherapy improve survival in upper tract urothelial carcinoma? A population based analysis
title_short Does perioperative chemotherapy improve survival in upper tract urothelial carcinoma? A population based analysis
title_sort does perioperative chemotherapy improve survival in upper tract urothelial carcinoma? a population based analysis
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5922356/
https://www.ncbi.nlm.nih.gov/pubmed/29721162
http://dx.doi.org/10.18632/oncotarget.24694
work_keys_str_mv AT goldberghanan doesperioperativechemotherapyimprovesurvivalinuppertracturothelialcarcinomaapopulationbasedanalysis
AT klaassenzachary doesperioperativechemotherapyimprovesurvivalinuppertracturothelialcarcinomaapopulationbasedanalysis
AT chandrasekarthenappan doesperioperativechemotherapyimprovesurvivalinuppertracturothelialcarcinomaapopulationbasedanalysis
AT sayyidrashid doesperioperativechemotherapyimprovesurvivalinuppertracturothelialcarcinomaapopulationbasedanalysis
AT kulkarnigirishs doesperioperativechemotherapyimprovesurvivalinuppertracturothelialcarcinomaapopulationbasedanalysis
AT hamiltonrobertj doesperioperativechemotherapyimprovesurvivalinuppertracturothelialcarcinomaapopulationbasedanalysis
AT fleshnerneile doesperioperativechemotherapyimprovesurvivalinuppertracturothelialcarcinomaapopulationbasedanalysis